Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with classical Hodgkin Lymphoma (a type of blood cancer), confirmed by a tissue sample test
- People who have not yet received any treatment for this condition
- People between the ages of 18 and 55 years old (confirm with trial site, as the upper age limit appears unclear in the source document)
- People who are generally well enough to carry out daily activities, based on a standard health scale (ECOG score of 2 or lower)
- People whose blood counts meet minimum levels — specifically, a certain type of infection-fighting white blood cell count above 1.0 x10⁹/L, and platelet count above 75 x10⁹/L
- People whose liver function results fall within acceptable levels, based on a substance called bilirubin being below a certain threshold
- People whose kidneys are functioning adequately, based on standard blood or urine tests
- Women who could potentially become pregnant must have a negative pregnancy test result taken under medical supervision, even if they have been using contraception
- People with a life expectancy of more than 6 months
- People who are able to attend all required study visits and follow the study's requirements
- People (or their legal representative) who are willing to sign a consent form showing they understand and agree to take part in the study
- People who have access to a PET-CT scanning facility (a specialised imaging scan used to monitor the condition)
Who may not be able to join:
- People whose Hodgkin Lymphoma is of a specific type called Nodular Lymphocyte Predominant Hodgkin Lymphoma
- People who have previously received chemotherapy or radiation therapy
- People who are pregnant or currently breastfeeding
- People with certain heart conditions, including irregular heartbeat, problems with the heart's electrical signals, reduced heart pumping function, or a specific heart measurement (left ventricular ejection fraction) of 50% or below on a heart ultrasound
- People with an abnormal result on a specific heart electrical test (QTc interval), above certain thresholds depending on sex
- People with an infection that is not currently under control
- People who are HIV positive, or who have active Hepatitis A, B, or C infection. People who test negative for active Hepatitis B but show signs of past exposure may still be considered, provided further specific blood tests are negative and they receive appropriate antiviral medication (confirm with trial site)
- People with diabetes that is not well managed
- People who are unwilling to use adequate contraception during the trial
- People with any medical or mental health condition that, in the treating doctor's judgement, could interfere with completing the treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vladislav Sarzhevskiy, PhD, State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phone: +7-910-436-00-40
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete remission rate (CR); Acute Toxicity; Late Toxicity; Event-Free Survival (EFS); Disease free survival (DFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.